Meet Omar*
Patient Background
- 63 years of age
- Relapsed DLBCL NOS
- Considered eligible for HSCT1-3
- Lives alone; has two adult daughters and grandchildren nearby
Clinical History1,2
- Two prior lines of systemic therapy
- 1st Line: Underwent chemoimmunotherapy (R-CHOP); achieved CR and relapsed after 18 months
- 2nd Line: Underwent three cycles of salvage chemotherapy and achieved CR; underwent high-dose chemotherapy and autologous HSCT; relapsed after 9 months
Clinical Stability1
- ECOG PS: 0
- LVEF: 45%
- Renal function: CrCl: 43 mL/min
When you see patients like Omar, think BREYANZI
CR: complete response; CrCl: creatinine clearance; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; HSCT: hematopoietic stem cell transplant; LVEF: left ventricular ejection fraction; NOS: not otherwise specified; R-CHOP: rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone.
* Fictitious patient case. May not be representative of the general population.
Meet Francis*
Patient Background
- 70 years of age
- Relapsed DLBCL NOS
- Considered ineligible for HSCT1-3
- Lives with his wife; his three adult children live locally and assist with medical care as needed
Clinical History1,3
- Two prior lines of systemic therapy
- 1st Line: Underwent chemoimmunotherapy (R-CHOP); achieved CR and relapsed after 9 months
- 2nd Line: Lack of response to salvage chemotherapy
- Additional information: localized extranodal disease
Clinical Stability1
- ECOG PS: 1
- LVEF: 42%
- Renal function: CrCl: 42 mL/min
When you see patients like Francis, think BREYANZI
CR: complete response; CrCl: creatinine clearance; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; HSCT: hematopoietic stem cell transplant; LVEF: left ventricular ejection fraction; NOS: not otherwise specified; R-CHOP: rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone.
* Fictitious patient case. May not be representative of the general population.
Meet Deanna*
Patient Background
- 50 years of age
- Relapsed DLBCL NOS
- Considered ineligible for HSCT1-3
- Lives with her spouse and teenaged son
Clinical History1,3
- Two prior lines of systemic therapy
- 1st Line: Refractory to chemoimmunotherapy (R-CHOP)
- 2nd Line: Lack of response to salvage chemotherapy
- Additional information: Double-hit lymphoma
Clinical Stability1
- ECOG PS: 0
- LVEF: 40%
- Renal function: CrCl: 36 mL/min
When you see patients like Deanna, think BREYANZI
CR: complete response; CrCl: creatinine clearance; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; HSCT: hematopoietic stem cell transplant; LVEF: left ventricular ejection fraction; NOS: not otherwise specified; R-CHOP: rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone.
* Fictitious patient case. May not be representative of the general population.
Learn more about the
safety profile of
BREYANZI
Explore the efficacy
profile of BREYANZI
Discover the Patient
Support Program for
BREYANZI
References:
1. BREYANZI Product Monograph. Bristol-Myers Squibb Company.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 23, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.
3. Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852.